secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-03-31T23:59:59+00:00
Accession:  0001437749-23-008871
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics restates 2021 financials, delays 10-K; reports $15M cash, reduced burn
--------------------------------------------------------------------------------

- Restatement of 2021 financials due to misclassification of insurance financing; no net income impact, but prior statements should no longer be relied upon.
- Cash and equivalents $15.0M as of Dec 31, 2022 (down from $33.2M); annualized cash consumption reduced to $18M from $60M.
- Received $16.8M total from US government settlement for COVID-19 therapeutic SAB-185; first $8.6M in Nov 2022, second $8.2M in Jan 2023.
- Raised $7.9M in private placement; appointed new CMO Alexandra Kropotova and board member Scott Giberson.
- Pipeline progress: SAB-142 type 1 diabetes IND-enabling studies completed; SAB-176 influenza Phase 2a data; SAB-195 C. diff program initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923008871/0001437749-23-008871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923008871/sabs20230330_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-008871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer